Acute myeloid leukemia (AML) comprises a heterogeneous group of leukemias frequently defined by recurrent cytogenetic abnormalities, including rearrangements involving the corebinding factor (CBF) transcriptional complex. To better understand the genomic landscape of CBF-AMLs, we analyzed both pediatric (n = 87) and adult (n = 78) samples, including cases with RUNX1-RUNX1T1 (n = 85) or CBFB-MYH11 (n = 80) rearrangements, by whole-genome or whole-exome sequencing. In addition to known mutations in the Ras pathway, we identified recurrent stabilizing mutations in CCND2, suggesting a previously unappreciated cooperating pathway in CBF-AML. Outside of signaling alterations, RUNX1-RUNX1T1 and CBFB-MYH11 AMLs demonstrated remarkably different spectra of cooperating mutations, as RUNX1-RUNX1T1 cases harbored recurrent mutations in DHX15 and ZBTB7A, as well as an enrichment of mutations in epigenetic regulators, including ASXL2 and the cohesin complex. This detailed analysis provides insights into the pathogenesis and development of CBF-AML, while highlighting dramatic differences in the landscapes of cooperating mutations for these related AML subtypes.
Acute myeloid leukemia (AML) comprises a heterogeneous group of leukemias frequently defined by recurrent cytogenetic abnormalities, including rearrangements involving the corebinding factor (CBF) transcriptional complex. To better understand the genomic landscape of CBF-AMLs, we analyzed both pediatric (n = 87) and adult (n = 78) samples, including cases with RUNX1-RUNX1T1 (n = 85) or CBFB-MYH11 (n = 80) rearrangements, by whole-genome or whole-exome sequencing. In addition to known mutations in the Ras pathway, we identified recurrent stabilizing mutations in CCND2, suggesting a previously unappreciated cooperating pathway in CBF-AML. Outside of signaling alterations, RUNX1-RUNX1T1 and CBFB-MYH11 AMLs demonstrated remarkably different spectra of cooperating mutations, as RUNX1-RUNX1T1 cases harbored recurrent mutations in DHX15 and ZBTB7A, as well as an enrichment of mutations in epigenetic regulators, including ASXL2 and the cohesin complex. This detailed analysis provides insights into the pathogenesis and development of CBF-AML, while highlighting dramatic differences in the landscapes of cooperating mutations for these related AML subtypes.
CBF-AMLs, which account for approximately 30% of pediatric and 15% of adult AMLs, contain chromosomal translocations or inversions that target the transcription factors RUNX1 (AML1) and CBFB. Normally, RUNX1 and CBFB heterodimerize to bind DNA and recruit lineage-defining transcription factors to regulate hematopoietic differentiation 1 . The fusion products found in CBF-AMLs (RUNX1-RUNX1T1/t(8;21)(q22;q22) or CBFB-MYH11/inv (16) (p13.1q22) or t(16;16)(p13.1;q22)) block myeloid differentiation but are not sufficient to induce leukemia, as the development of leukemia in mouse models of both fusions requires secondary mutations, including ones in the Ras pathway [2] [3] [4] [5] .
Whereas initial studies focused on validating known mutations, especially those in the Ras pathway [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] , and recent profiling studies focused on limited gene sets [18] [19] [20] or had limited sample numbers [21] [22] [23] , we sought to comprehensively understand genetic variations contributing to CBF-AML development by analyzing 165 cases by wholegenome sequencing (n = 17) or whole-exome sequencing (n = 148) ( Table 1 and Supplementary Table 1) . In this cohort, the age distributions of patients with RUNX1-RUNX1T1 (n = 85) and CBFB-MYH11 (n = 80) rearrangements were comparable, as were outcomes (Supplementary Fig. 1 ). An average of 9.86 ± 6.16 (s.d.) somatic mutations with functional consequences were identified per case, with more mutations found in RUNX1-RUNX1T1 cases (11.86 ± 6.40 versus 7.74 ± 5.13 for CBFB-MYH11 cases; P < 0.0001) and adult cases (12.56 ± 6.55 versus 7.44 ± 4.62 for pediatric cases; P < 0.0001) ( Supplementary Fig. 2 and Supplementary Tables 2-7) , although the spectrum of mutations for both CBF-AML subtypes was similar to the previously reported signature for AML 24 (Supplementary Fig. 3 ). Subclonal variants were identified in all CBF-AMLs analyzed by whole-genome sequencing followed by capture validation at >1,200× coverage, consistent with other AMLs 25, 26 (Supplementary Fig. 4 ). Few copy number alterations (CNAs) or additional structural variations ( Supplementary Fig. 5 and Supplementary Tables 8 and 9) were present. Consistent with previous reports 14, 27, 28 The genomic landscape of core-binding factor acute myeloid leukemias 1 5 5 2 VOLUME 48 | NUMBER 12 | DECEMBER 2016 Nature GeNetics l e t t e r s and/or loss-of-function mutations in NF1 (Fig. 1) ; cumulatively, these mutations were not associated with outcome ( Supplementary  Fig. 6 ). NRAS was the most frequently mutated gene in CBF-AMLs, yet its mutation was not associated with outcome (P = 0.638). Not only were NRAS mutations more common in CBFB-MYH11 AMLs (P = 0.032), but the spectrum of mutations was also different, as codon 61 mutations were more common in CBFB-MYH11 cases (P = 0.0023; Supplementary Fig. 7 ). Additionally, there was an enrichment of KIT exon 17 mutations (P = 0.0051) in the RUNX1-RUNX1T1 cohort 13, 15 , which were associated with worse outcome (P = 0.0097; Supplementary Figs. 6, 8 and 9 , and Supplementary Note).
MGA, a negative regulator of MYC signaling 29 , was also recurrently mutated in CBF-AMLs (Fig. 2) . The MGA mutations in RUNX1-RUNX1T1 AMLs were all predicted to be deleterious (including the splice-site variant) and would eliminate the helix-loop-helix domain and binding of MGA to MAX 29 (Fig. 2) . Similar loss-of-function mutations in MGA have recently been identified in lung cancer, chronic 80  43  37  10  70  9   Total  165  87  78  17  148  36 WES, whole-exome sequencing; WGS, whole-genome sequencing. l e t t e r s lymphocytic leukemia, ETV6-RUNX1 acute lymphoblastic leukemia, NK/T cell lymphomas and a single case of RUNX1-RUNX1T1 AML in the AML TCGA (The Cancer Genome Atlas) study 25, [30] [31] [32] [33] [34] . We also found three cases with MYC mutations and seven cases (five RUNX1-RUNX1T1 and two CBFB-MYH11) with mutations in CCND2 (cyclin D2), a known downstream target of MYC 35 . All CCND2 mutations ( Fig.  2 and Supplementary Fig. 10 ) surrounded the codon for a conserved phosphorylation site (Thr280) that regulates ubiquitination of Lys270 by FBXL2 (ref. 36 ) and degradation by the proteosome 37 . Germline and somatic mutations in this region of CCND2 have been identified in patients with megalencephaly-polymicrogyria-polydactyly -hydrocephalus (MPPH) syndrome 38 but have been uncommon in myeloid malignancies 25, 39 . Much like the germline mutations found in MPPH syndrome, the CCND2 mutations identified here led to increased stability of the CCND2 protein ( Fig. 2 and Supplementary  Fig. 10 ). Collectively, these data suggest that stabilization of CCND2 is a previously unidentified and potentially targetable mutation in CBF-AML. Recurrent p.Arg222Gly alterations in DHX15 (NM_001358.2: c.832C>G), a member of the DExD/H-box family of RNA helicases whose yeast homolog (Prp43) participates in spliceosome function and ribosomal biogenesis [40] [41] [42] [43] , were also identified exclusively in the RUNX1-RUNX1T1 cohort. Interestingly, ribosomal biogenesis is also affected by RUNX1 deficiency 44 . The p.Arg222Gly missense alteration lies in the back of the RecA1 domain along the translocation site and is therefore unlikely to affect the ATPase activity or RNA-binding ability of DHX15 ( Supplementary Fig. 11 ). We used RNA interference (RNAi)-mediated knockdown of DHX15 to mimic a complete loss of function and observed differential expression of splicing genes and genes involved in ribosomal biogenesis ( Supplementary Fig. 12 and Supplementary Tables 10-12) as well as an increase in the number of alternative splicing events upon loss of DHX15 protein. A similar increase in the number of alternative splicing events was obtained when the Arg222Gly mutant was overexpressed in vitro. These data led us to examine proteins differentially bound to the wild-type and mutant DHX15 proteins via mass spectroscopy and coimmunoprecipitation (Supplementary Table 13 ). We found that TFIP11, a component of the splicing machinery, exhibited reduced binding to the DHX15 Arg222Gly mutant (Fig. 3) . Whereas DHX15 mutations are common in RUNX1-RUNX1T1 cases 21, 23 , other myeloid neoplasms harbor mutations in different spliceosome components (for example, SF3B1 and U2AF1) 45 , which were not observed in CBF-AMLs.
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A striking and statistically significant enrichment for putative lossof-function mutations in chromatin-modifying genes (ASXL2, EZH2, KDM6A, EED, SETD2, KMT2D, KMT2C and CREBBP) was observed in the RUNX1-RUNX1T1 cases (44% versus 4% in CBFB-MYH11 cases; P = 4.3 × 10 −10 ; Fig. 1 and Supplementary Fig. 13 ). Consistent with previous reports, frameshift mutations in ASXL2 were common and were found exclusively in RUNX1-RUNX1T1 CBF-AMLs 46, 47 . These mutations were identified in both pediatric and adult cases, and were not associated with outcome ( Supplementary Fig. 14) . These truncating mutations would eliminate the PHD protein-protein interaction domain and are similar to mutations in ASXL1 that inhibit myeloid differentiation and induce a myelodysplastic syndrome (MDS)-like disease in mice 48, 49 . Whether ASXL2 modulates Polycomb repressive complex 2 (PRC2) function, like ASXL1, however, is currently unknown 48 . In vitro studies using two separate ASXL2 mutations suggested that ASXL2 may have a role in myeloid differentiation (Supplementary Fig. 15 ). We did not identify mutations in ASXL1 in the de novo leukemias, despite adequate sequence coverage in our whole-exome sequencing cohort (Supplementary Fig. 16 ). Many of the other mutated epigenetic regulators, such as KMT2C 50,51 , KDM6A 52 and CREBBP 53 , functionally interact in complexes that alter enhancer state 54 , suggesting that enhancer dysregulation may be an important cooperating event with RUNX1-RUNX1T1 rearrangement. As such, a recent study observed that disruption of Kmt2c in a RUNX1-RUNX1T1 mouse model was associated with chemotherapy resistance 55 . Interestingly, of the four patients with KMT2C mutations in our cohort, three relapsed in <12 months and the fourth had residual disease after one course of remission-induction therapy.
Mutations affecting components of the cohesin complex (n = 17) were exclusively identified in RUNX1-RUNX1T1 AMLs (Supplementary Fig. 17) . SMC1A, SMC3 and RAD21 encode members of the complex responsible for sister chromatid cohesion during mitosis and post-replicative DNA repair 56 . Mutations in these genes have been reported in AML 19, 57, 58 , and germline mutations represent some of the underlying causes of the cohesinopathies 56, 59 . The 17 cases with mutations in cohesin genes lacked evidence of aneuploidy or an increased rate of DNA mutation (Supplementary Tables 1 and 2 ), and mutation status had no effect on outcome ( Supplementary  Fig. 18 ). We speculate that these mutations, similar to those in the epigenetic regulators mentioned above, alter transcriptional programs by dysregulating enhancer function 50 . We also identified recurrent mutations in ZBTB7A (also called Pokemon; Supplementary Fig. 19 ). 
l e t t e r s
The putative loss-of-function mutations identified here are consistent with recent reports of ZBTB7A acting as a tumor suppressor in RUNX1-RUNX1T1 AML 22, 60 .
We performed transcriptome analysis on the 36 (27 RUNX1-RUNX1T1 and 9 CBFB-MYH11) cases for which material was available. Differential expression analysis generated data consistent with previous array-based studies 61, 62 ( Supplementary Fig. 20 and Supplementary Tables 14-16 ), yet differences due to mutations in specific genes could not be definitively determined because of our relatively small sample size. We were able to detect the alternatively spliced 9A isoform of RUNX1T1 in every RUNX1-RUNX1T1 case, ranging in abundance from 13 to 64% of the transcripts (Supplementary Fig. 21 ) 63 .
Relapse material was characterized by whole-exome sequencing for eight samples in the cohort, demonstrating dynamic patterns of clonal evolution during disease progression, including loss, retention or gain of somatic mutations and CNAs (Fig. 4, Supplementary Fig. 22 and Supplementary Tables 17 and 18 ). For example, multiclonal KIT mutations were present at diagnosis in one case, with expansion of only one subclonal population at relapse, whereas another case retained a KRAS mutation while losing a KIT mutation at relapse (Supplementary Fig. 22 ).
Despite sharing a common molecular alteration involving a component of the CBF transcription complex, AMLs with RUNX1-RUNX1T1 and CBFB-MYH11 alterations have remarkably different spectra of cooperating mutations (Supplementary Fig. 23 ). Mutations in signaling components are common in both subtypes, yet RUNX1-RUNX1T1 cases have different types of signaling alterations that include mutations of CCND2. Mutations involving epigenetic regulators and the cohesin complex, as well as mutations in DHX15 and ZBTB7A, are also frequently observed in RUNX1-RUNX1T1 cases. While these results are suggestive of these components having a functional role in RUNX1-RUNX1T1 leukemogenesis, future studies will be required to evaluate their role in CBF-AML pathogenesis. 
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Subject cohorts and sample details. Tumor and germline samples from pediatric CBF-AMLs from the St. Jude Children's Research Hospital tissue resource core facility and adult CBF-AMLs from the University Hospital of Ulm were obtained with informed consent using a protocol approved by the St. Jude Children's Research Hospital institutional review board. Detailed clinicopathological and sequencing information is provided in Supplementary Tables 1-9 . The study cohort comprised 165 leukemias (85 RUNX1-RUNX1T1 and 80 CBFB-MYH11 samples with matched germline samples) in two cohorts: a cohort for whole-genome sequencing (n = 17; 7 RUNX1-RUNX1T1 and 10 CBFB-MYH11 cases, all pediatric) and a cohort for whole-exome sequencing (n = 148; 78 RUNX1-RUNX1T1 and 70 CBFB-MYH11 cases). Matched germline DNA was acquired at remission from either bone marrow or peripheral blood or was flow sorted from leukemic samples.
Whole-genome and whole-exome sequencing and analysis. Whole-genome and whole-exome sequencing were performed as previously described 64, 65 . Paired-end sequencing was performed using the Illumina HiSeq platform with a read length of 100 bp. Whole-genome sequencing mapping, coverage and quality assessment, single-nucleotide variant (SNV) and indel detection, tier annotation for sequence mutations and prediction of the deleterious effects of missense mutations have been described previously 64, 65 . Mapping statistics and coverage for each tumor are summarized in Supplementary  Tables 3 and 4 . SNVs discovered by whole-genome sequencing were classified as tier 1, tier 2, tier 3 or tier 4 as previously described 64, 65 . All tier 1-3 SNVs were validated by a custom capture platform, as well as all coding indels and structural variations (Supplementary Table 5 ). The overall validation rate was 83%, with a median validation rate of 87% per sample. All recurrent SNVs (Supplementary Table 6 ) in the whole-exome sequencing cohort were validated by either amplicon sequencing using the MiSeq platform or Sanger sequencing, as previously described 64, 65 . Briefly, PCR primers were designed to flank the putative variant using Primer3. Amplicon sizes ranged from approximately 400 bp to 600 bp. PCR was performed using AmpliTaq Gold 360 master mix (Applied Biosystems), 400 nM of each primer (IDT) and 20 ng of repli-G whole-genome-amplified DNA (Qiagen) in a 25-µl reaction volume. Thermocycling was performed using the following parameters: 95 °C for 10 min; 95 °C for 30 s, 65 °C for 30 s and 72 °C for 1 min for 35 cycles; and 72 °C for 7 min. All amplicons were quality checked on a 2% agarose E-gel (Invitrogen). Pooled amplicons were used to create DNA libraries using the Nextera XT kit (Illumina) following the manufacturer's instructions. Libraries were normalized and sequenced on an Illumina MiSeq instrument using a 2 × 150 paired-end version 2 sequencing kit. Sanger sequencing was also performed on a subset of amplicons. The primer pairs and SNV targets used in validation are included in Supplementary Table 18 . All validated SNVs are summarized in Supplementary Table 7 . CNAs that were identified from whole-genome sequencing data were analyzed by evaluating the difference in read depth between each tumor and its matching normal (germline) sample using CONSERTING 66 (Supplementary Table 8 ). Other CNAs were detected by Affymetrix SNP 6.0 array, as previously described 28, 29 . Structural variations in whole-genome sequencing data were analyzed using CREST and were annotated as previously described 64, 67 (Supplementary Table 9 ). To assess tumor contamination of the germline sample, we evaluated the existence of structural variations supporting the RUNX1-RUNX1T1 and CBFB-MYH11 fusions in germline samples using CREST 67 . The level of tumor contamination in normal samples was calculated as the number of reads supporting fusion divided by the total number of reads and was under the limit of detection in each sample (Supplementary Table 3 ).
Transcriptome sequencing. For library construction, 2-5 µg of total RNA was extracted from tumor samples using Qiagen RNeasy Mini kits according to the manufacturer's instructions. RNA concentration was measured using a NanoDrop 100 spectrophotometer (Thermo Scientific). RNA integrity was measured using an Agilent Technologies 2100 Bioanalyzer Lab-on-a-Chip system. Total RNA was treated with DNase I (Invitrogen) and enriched for poly(A)-containing mRNA using oligo(dT) beads (Dynabeads, Invitrogen). cDNA synthesis was performed using random hexamers and the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen). Paired-end reads from mRNA-seq were aligned to the following four database files using BurrowsWheeler aligner (0.5.5): (i) the human NCBI Build 37 reference sequence, (ii) RefSeq, (iii) a sequence file representing all possible combinations of non-sequential pairs in RefSeq exons, and (iv) the AceView flat file downloaded from UCSC, representing transcripts constructed from human ESTs. The final BAM (compressed binary version of the Sequence Alignment/Map (SAM) format) file was constructed by selecting the best alignment from the four databases.
CNA detection using whole-exome sequencing data. The SAMtools 68 mpileup command was used to generate an mpileup file from matched normal and tumor BAM files, with duplicates removed. VarScan2 (ref. 69 ) was then used to take the mpileup file to call somatic CNAs after adjusting for normal/ tumor sample read coverage depth and GC content. The circular binary segmentation algorithm 70 implemented in the DNAcopy R package was used to identify candidate CNAs for each sample. B-allele frequency information for all high-quality dbSNPs heterozygous in the germline sample was also used to assess allele imbalance. Transient transfection with CCND2 mutants. HEK293T cells (American Type Culture Collection (ATCC); cells tested for mycoplasma by ATCC) were transiently transfected using FuGene HD (Promega) according to the manufacturer's instructions. HEK293T cells were used because of their ease of culture and transfection, and have been widely used as hosts for gene expression. Cells were incubated for 24 h and then subjected to 50 µg/ml cycloheximide and collected at the indicated time points in NP-40 lysis buffer (150 mM NaCl, 1% NP-40 and 50 mM Tris, pH 8.0) supplemented with Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific). Immunoblotting of HEK293T cells expressing CCND2 constructs was performed using 10 µg of protein lysates prepared using NuPAGE LDS buffer (Life Technologies) electrophoresed through 4-12% NuPAGE Bis-TRIS gels under reducing conditions. After protein was transferred to PVDF membrane (iBlot, Life Technologies), membranes were probed with antibodies to total CCND2 (Abcam, ab3085; 1:1,000 dilution) and GAPDH (Santa Cruz Biotechnology, 6C5; 1:5,000 dilution) using the iBind system (Life Technologies). Quantification of immunoblots was performed using ImageJ software. RNA was extracted after 48 h with TRIzol reagent, and libraries were prepared as described above. Pulldown experiments for mass spectrometry were carried out using the Pierce c-Myc Tag IP/Co-IP kit (Thermo Scientific). The mass spectrometry analysis was performed according to the optimized platform as previously reported 73 . Proteins in the gel band were digested in the gel with trypsin. Resulting peptides were loaded onto a nanoscale reverse-phase column and eluted by a gradient (~30 min). Eluted peptides were detected by an inline LTQ Orbitrap Elite mass spectrometer (Thermo Scientific). Acquired data were searched against the protein database using the Sequest algorithm and filtered to reduce the protein false discovery rate (FDR) to below 1%. For binary comparison, statistical analysis was also performed on the basis of the G test. FDR was derived according to biological replicates and the null hypothesis 74 .
Modeling of DHX15.
Immunoblotting and coimmunoprecipitation. Coimmunoprecipitation and immunoblotting used standard techniques as described previously 75 . Briefly, mouse embryonic fibroblasts were transduced to stably coexpress human TFIP11 (2× Myc tagged) with either wild-type or Arg222Gly mutant human DHX15 (2× HA tagged). Cells were lysed in NP-40 buffer (0.5% NP-40, 20 mM Tris, pH 7.5, 137 mM NaCl, 2 mM EDTA, 10% glycerol and 100 µg/ml RNase A). Agarose-conjugated antibody to HA (Roche, 3F10) or Myc (Cell Signaling Technology, 9B11) was used for coimmunoprecipitation ( Supplementary Fig. 24 ). Horseradish peroxidase (HRP)-conjugated antibody to HA (Roche, 3F10; 100 ng/ml) or Myc (Cell Signaling Technology, 9B11; 1: 3,000 dilution) was used for immunoblot analysis.
Gene set enrichment analysis. Array data from Ross et al. 62 were used for limma 76 analysis to create a list of genes differentially expressed between cases of RUNX1-RUNX1T1 and CBFB-MYH11 CBF leukemia (Supplementary Table 16 ). The resulting gene list was truncated at an FDR of 0.001, and the remaining genes were used to create a gene set that represented the gene signature of each fusion. The transcriptome data were then used for gene set enrichment analysis 77 .
Mutational spectrum analysis. We used a published computational framework for mutation signature identification 24, 78 . The algorithm deciphers the minimal set of mutational signatures that optimally explains the proportion of each mutation type found in each catalog and then estimates the contribution of each signature to each catalog. We used somatic mutations called from the whole-exome sequencing diagnostic samples of RUNX1-RUNX1T1 (70 samples, 1,595 mutations) and CBFB-MYH11 (66 samples, 1,024 mutations).
Statistical methods. Enrichment in the number of cases harboring mutations in NRAS and epigenetic and cohesin genes in the RUNX1-RUNX1T1 versus CBFB-MYH11 cohorts was calculated using Fisher's exact test. Enrichment of NRAS codon 61 and KIT exon 17 mutations between the subtypes was also calculated using Fisher's exact test. Differences in the expression level of CCND2 were calculated using Student's t test. Differences in total numbers of functional mutations between the groups based on age or translocation were calculated using the exact Wilcoxon rank-sum test based on 10,000 permutations. The association of a mutation with event-free survival or overall survival was assessed using the Cox proportional hazard model; survival curves were also compared by log-rank test. Event-free survival was defined as the time elapsed from the on-study date to the date of induction failure, withdrawal, relapse, secondary malignancy or death, with those living and event free at the last follow-up censored. Overall survival was defined as the time elapsed from the on-study date to the date of death, with those still living at the last follow-up considered censored. Outcome data were available for 159 of 165 patients with CBF-AML.
